James W Dear1. 1. Pharmacology, Therapeutics and Toxicology Unit, Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK. Electronic address: james.dear@ed.ac.uk.
The POP Trial Investigators read with interest this letter from Dr. Karlsson [1] regarding the results of our Phase 1 trial [2]. We agree that all safety information from this trial is important for our planning of future trials.The frequency of gastrointestinal adverse events and serious adverse events in the 4 different treatment groups is already presented in Supplementary Table 2 [2]. These adverse events were nausea, vomiting or abdominal pain – all symptoms that are common after a paracetamoloverdose treated with acetylcysteine.No patient in this trial developed diarrhoea.
Authors: Emma E Morrison; Katherine Oatey; Bernadette Gallagher; Julia Grahamslaw; Rachel O'Brien; Polly Black; Wilna Oosthuyzen; Robert J Lee; Christopher J Weir; Dennis Henriksen; James W Dear Journal: EBioMedicine Date: 2019-07-13 Impact factor: 8.143